Hepatitis C Virus Management: Potential Impact of Nanotechnology

Overview

Journal Virol J

Publisher Biomed Central

Specialty Microbiology

Date 2017 May 4

PMID 28464951

Citations 11

Authors

Mostafa H Elberry

Noureldien H E Darwish

Shaker A Mousa

Affiliations

Soon will be listed here.

Abstract

Around 170-200 million individuals have hepatitis C virus (HCV), which represents ~ 3% of the world population, including ~ 3-5 million people in the USA. According to the WHO regional office in the Middle East, Egypt has the highest prevalence in the world, with 7% prevalence in adults. There had been no effective vaccine for HCV; a combination of PEG-Interferon and ribavirin for at least 48 weeks was the standard therapy, but it failed in more than 40% of the patients and has a high cost and serious side effects. The recent introduction of direct-acting antivirals (DAA) resulted in major advances toward the cure of HCV. However, relapse and reduced antiviral efficacy in fibrotic, cirrhotic HCV patients in addition to some undesired effects restrain the full potential of these combinations. There is a need for new approaches for the combinations of different DAA and their targeted delivery using novel nanotechnology approaches. In this review, the role of nanoparticles as a carrier for HCV vaccines, anti-HCV combinations, and their targeted delivery are discussed.

Citing Articles

Current and emerging strategies for the prevention of hepatocellular carcinoma.

Yeo Y, Abdelmalek M, Khan S, Moylan C, Rodriquez L, Villanueva A Nat Rev Gastroenterol Hepatol. 2024; 22(3):173-190.

PMID: 39653784 DOI: 10.1038/s41575-024-01021-z.

Hepatocyte targeting the asialoglycoprotein receptor.

Ramirez-Cortes F, Menova P RSC Med Chem. 2024; 16(2):525-544.

PMID: 39628900 PMC: 11609720. DOI: 10.1039/d4md00652f.

A therapeutic approach for the hepatitis C virus: in silico design of an antisense oligonucleotide-based candidate capsid inhibitor.

Hasturk B, Eren F Virus Genes. 2024; 60(5):446-454.

PMID: 39083128 DOI: 10.1007/s11262-024-02088-1.

Therapeutic strategies and promising vaccine for hepatitis C virus infection.

Adugna A Immun Inflamm Dis. 2023; 11(8):e977.

PMID: 37647422 PMC: 10461427. DOI: 10.1002/iid3.977.

Glycomimetics for the inhibition and modulation of lectins.

Leusmann S, Menova P, Shanin E, Titz A, Rademacher C Chem Soc Rev. 2023; 52(11):3663-3740.

PMID: 37232696 PMC: 10243309. DOI: 10.1039/d2cs00954d.

References

Schekman R, Singer S . Clustering and endocytosis of membrane receptors can be induced in mature erythrocytes of neonatal but not adult humans. Proc Natl Acad Sci U S A. 1976; 73(11):4075-9. PMC: 431333. DOI: 10.1073/pnas.73.11.4075. View

Bartenschlager R, Lohmann V . Replication of hepatitis C virus. J Gen Virol. 2000; 81(Pt 7):1631-48. DOI: 10.1099/0022-1317-81-7-1631. View

Lauer G, Walker B . Hepatitis C virus infection. N Engl J Med. 2001; 345(1):41-52. DOI: 10.1056/NEJM200107053450107. View

Pallaoro M, Lahm A, Biasiol G, Brunetti M, Nardella C, Orsatti L . Characterization of the hepatitis C virus NS2/3 processing reaction by using a purified precursor protein. J Virol. 2001; 75(20):9939-46. PMC: 114565. DOI: 10.1128/JVI.75.20.9939-9946.2001. View

Alter M . Prevention of spread of hepatitis C. Hepatology. 2002; 36(5 Suppl 1):S93-8. DOI: 10.1053/jhep.2002.36389. View

Kapadia S, Brideau-Andersen A, Chisari F . Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci U S A. 2003; 100(4):2014-8. PMC: 149950. DOI: 10.1073/pnas.252783999. View

Tsukiyama-Kohara K, Iizuka N, Kohara M, Nomoto A . Internal ribosome entry site within hepatitis C virus RNA. J Virol. 1992; 66(3):1476-83. PMC: 240872. DOI: 10.1128/JVI.66.3.1476-1483.1992. View

Agrawal N, Dasaradhi P, Mohmmed A, Malhotra P, Bhatnagar R, Mukherjee S . RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev. 2003; 67(4):657-85. PMC: 309050. DOI: 10.1128/MMBR.67.4.657-685.2003. View

Jiao X, Wang R, Qiu Q, Alter H, Shih J . Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes. J Gen Virol. 2004; 85(Pt 6):1545-1553. DOI: 10.1099/vir.0.79896-0. View

10.

Shepard C, Finelli L, Alter M . Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5(9):558-67. DOI: 10.1016/S1473-3099(05)70216-4. View

11.

Rothen-Rutishauser B, Schurch S, Haenni B, Kapp N, Gehr P . Interaction of fine particles and nanoparticles with red blood cells visualized with advanced microscopic techniques. Environ Sci Technol. 2006; 40(14):4353-9. DOI: 10.1021/es0522635. View

12.

Katas H, Alpar H . Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release. 2006; 115(2):216-25. DOI: 10.1016/j.jconrel.2006.07.021. View

13.

Bartenschlager R, Sparacio S . Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture. Virus Res. 2007; 127(2):195-207. DOI: 10.1016/j.virusres.2007.02.022. View

14.

Appaiahgari M, Vrati S . DNAzyme-mediated inhibition of Japanese encephalitis virus replication in mouse brain. Mol Ther. 2007; 15(9):1593-9. DOI: 10.1038/sj.mt.6300231. View

15.

Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland S, Isogawa M . A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A. 2008; 105(8):3088-93. PMC: 2268589. DOI: 10.1073/pnas.0712380105. View

16.

Bobardt M, Cheng G, de Witte L, Selvarajah S, Chatterji U, Sanders-Beer B . Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus. Proc Natl Acad Sci U S A. 2008; 105(14):5525-30. PMC: 2291127. DOI: 10.1073/pnas.0801388105. View

17.

Sosnik A, Amiji M . Nanotechnology solutions for infectious diseases in developing nations. Preface. Adv Drug Deliv Rev. 2009; 62(4-5):375-7. DOI: 10.1016/j.addr.2009.11.010. View

18.

Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, Brillet R . Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology. 2009; 138(3):1112-22. DOI: 10.1053/j.gastro.2009.11.053. View

19.

Lanford R, Hildebrandt-Eriksen E, Petri A, Persson R, Lindow M, Munk M . Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2009; 327(5962):198-201. PMC: 3436126. DOI: 10.1126/science.1178178. View

20.

Wagoner J, Negash A, Kane O, Martinez L, Nahmias Y, Bourne N . Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology. 2010; 51(6):1912-21. PMC: 2909978. DOI: 10.1002/hep.23587. View